Warfarin

Summary of changes

Addition 

  • POC test for INR
  • Advice on medications and adjusting warfarin

Deletion

  • Tables stating doses and dose adjustments for target range of 2.0–3.0 and 2.5–3.5

Other

  • Protocol shortened to key principles

Primary references

  1. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM and Palareti G (2012) 'Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines', Chest, 141(2 Suppl):e44S-e88S, doi:10.1378/chest.11-2292

  2. Australasian Society of Thrombosis and Haemostasis (2013) 'An update of consensus guidelines for warfarin reversal', Medical Journal of Australia, 198(4):198-9, doi:10.5694/mja12.10614

  3. Expert Group for Toxicology and Toxinology, version 1 (2020) Warfarin poisoning, Therapeutic Guidelines, accessed 5 October 2022.

  4. Queensland Health and the Royal Flying Doctor Service (Queensland Section) (2016) Guidelines for Warfarin Management in the Community, accessed 5 October 2022.

  5. Schulman S, Parpia S, Stewart C, Rudd-Scott L, Julian JA and Levine M (2011) 'Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial', Annals of Internal Medicine, 155(10):653-9, doi:10.7326/0003-4819-155-10-201111150-00003

  6. Tideman PA, Tirimacco R, John AS and Roberts GW (2015) 'How to manage warfarin therapy', Australian Prescriber, 38(2):44-8, doi:10.18773/austprescr.2015.016

Indigenous/remote context references

  1. Rheumatic Heart Disease Australia (ARF/RHD writing group) (2020) The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease, 3rd edition, accessed 11 January 2022.